EGFR and non-small cell lung carcinoma: Moreover, the results of the FLAURA phase III study displayed superiority in prolonged PFS and OS (PFS: 18.9 months vs. 10.2 months; OS: 38.6 months vs. 31.8 months) for advanced or metastatic NSCLC patients with first-line osimertinib treatment, compared with first-generation EGFR-TKI (gefitinib, erlotinib) treatment [34,35].